Novel Inhibitor of Mixed-Lineage Kinase Domain-Like Protein: The Antifibrotic Effects of a Necroptosis Antagonist

The pseudokinase mixed-lineage kinase domain-like protein plays a crucial role in programmed cell death via necroptosis. We developed a novel mixed-lineage kinase domain-like inhibitor, P28, which demonstrated potent necroptosis inhibition and antifibrotic effects. P28 treatment directly inhibited m...

Full description

Saved in:
Bibliographic Details
Published in:ACS pharmacology & translational science 2023-10, Vol.6 (10), p.1471-1479
Main Authors: Oh, Ju Hee, Park, Sunyou, Hong, Eunmi, Choi, Myeong A., Kwon, Ye-Mi, Park, Jin-wan, Lee, A. Hyeon, Park, Gye Ryeol, Kim, Hye Young, Lee, Seung Min, Lee, Ju Yeon, Bae, Sang Hyun, Lee, Ji Hoon, Lee, Jung Yeol, Jun, Dae Won
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The pseudokinase mixed-lineage kinase domain-like protein plays a crucial role in programmed cell death via necroptosis. We developed a novel mixed-lineage kinase domain-like inhibitor, P28, which demonstrated potent necroptosis inhibition and antifibrotic effects. P28 treatment directly inhibited mixed-lineage kinase domain-like phosphorylation and oligomerization after necroptosis induction, inhibited immune cell death after necroptosis, and reduced the expression of adhesion molecules. Additionally, P28 treatment reduced the level of activation of hepatic stellate cells and the expression of hepatic fibrosis markers induced by necroptosis stimulation. Unlike the necrosulfonamide treatment, the P28 treatment did not induce cytotoxicity. Finally, the cysteine covalent bonding of P28 was confirmed by liquid chromatography–tandem mass spectrometry.
ISSN:2575-9108
2575-9108
DOI:10.1021/acsptsci.3c00131